Building on research by a former University of Minnesota professor, Torigen Pharmaceuticals has begun in-veterinary testing of its immunooncology vaccine for companion animals.

Torigen Pharmaceuticals, a US-based veterinary cancer immunotherapy developer based on University of Minnesota research, has closed a $3.1m series A round featuring University of Connecticut-backed UConn Innovation Fund.
UConn Innovation Fund, which also counts state-owned investment firm Connecticut Innovations (CI) and financial services Webster Bank as partners, is a $1.5m vehicle open to participants in the UConn Technology Incubation Program.
CI led the series A round in its own right, with participation from SoGal Ventures, The Fund and assorted angel investors. The deal includes conversions of existing debt and interest instruments.
Founded in 2013, Torigen Pharmaceuticals develops immuno-oncology products for pets based on its research and development platform.
The company’s initial product is already available to veterinary surgeries on an experimental basis. It works by extracting a section of the animal tumour to create a personalised cancer vaccine that empowers the pet’s immune system to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?